Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Vice President,Finance & Admin | July 01, 2022 | February 07, 2023 |
| ImageneBio, Inc.IMA · Entity 7139 | Principal Accounting Officer | December 30, 2025 | January 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date July 01, 2022 · Filed February 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.28 · Expires 2027-09-17 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the Issuer's 2016 Equity Incentive Plan (the "2016 EIP"). All 714 stock options are fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.15 · Expires 2029-05-22 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. 11,250 of the stock options are fully vested and exercisable. 3,750 of the stock options will vest on May 22, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.14 · Expires 2031-03-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. 7,500 of the stock options are fully vested and exercisable. 7,500 of the stock options will vest on March 25, 2023, 7,500 of the stock options will vest on March 25, 2024, and 7,500 of the stock options will vest on March 25, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.11 · Expires 2032-04-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-07-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. None of the stock options have fully vested and become exercisable. 12,500 of the stock options will vest on April 13, 2023, 12,500 of the stock options will vest on April 13, 2024, 12,500 of the stock options will vest on April 13, 2025, and 12,500 of the stock options will vest on April 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the Issuer's 2016 Equity Incentive Plan (the "2016 EIP"). All 714 stock options are fully vested and exercisable.
F2: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. 11,250 of the stock options are fully vested and exercisable. 3,750 of the stock options will vest on May 22, 2023.
F3: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. 7,500 of the stock options are fully vested and exercisable. 7,500 of the stock options will vest on March 25, 2023, 7,500 of the stock options will vest on March 25, 2024, and 7,500 of the stock options will vest on March 25, 2025.
F4: Reflects the grant of stock options to purchase shares of common stock of the Issuer under the 2016 EIP. None of the stock options have fully vested and become exercisable. 12,500 of the stock options will vest on April 13, 2023, 12,500 of the stock options will vest on April 13, 2024, 12,500 of the stock options will vest on April 13, 2025, and 12,500 of the stock options will vest on April 13, 2026.
ImageneBio, Inc.
Report date December 30, 2025 · Filed January 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,551 |
Reported balance
After 2025-12-30 transaction · row 1
1 source rowRow 1 · 2025-12-30 · Grant · Acquired 22,500 · Balance 25,551 F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on July 15, 2026, March 1, 2027, March 1, 2028 and March 1, 2029, in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such date. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.11 · Expires 2035-12-30 | Direct | 22,500 |
Reported balance
After 2025-12-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-30 · Grant · Acquired 22,500 · Balance 22,500 F2: This option vests over four years, with 25% of the shares subject to this option vesting on July 15, 2026, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on July 15, 2026, March 1, 2027, March 1, 2028 and March 1, 2029, in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such date.
F2: This option vests over four years, with 25% of the shares subject to this option vesting on July 15, 2026, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2025 Filed Jan 3, 2026 02:15 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0001940413-26-000001 · form4-01032026_020151.xml · derivative · entry 2 Butler Erin · CIK 0001940413 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2035-12-30 F2 · derivative.exercise_date: This option vests over four years, with 25% of the shares subject to this option vesting on July 15, 2026, and the remaining shares vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2025 Plan) through each such date. Read SEC document |
| December 30, 2025 Filed Jan 3, 2026 02:15 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001940413-26-000001 · form4-01032026_020151.xml · nonDerivative · entry 1 Butler Erin · CIK 0001940413 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,551 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on July 15, 2026, March 1, 2027, March 1, 2028 and March 1, 2029, in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan")) through each such date. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 23:02 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantEmployee Stock Option (right to buy) · Derivative | 3,813 | Not disclosed Strike: $4.59 | Not disclosed |
DisclosureSEC source: 0001415889-25-020511 · form4-07292025_110730.xml · derivative · entry 2 Butler Erin · CIK 0001940413 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,813 Underlying: Common Stock · 3,813 shares Expires 2027-10-16 F2 · price: Under the terms of the Merger Agreement, on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "Merger"), with Legacy Inmagene surviving the Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). Upon the closing of the First Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. to ImageneBio, Inc. F4 · price: Received in exchange for a stock option to acquire 1,250,000 shares of common stock of Legacy Inmagene with the exercise price of $0.014 per share pursuant to the Merger Agreement. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on the one year anniversary of the vesting commencement date and the balance of the shares vested or will vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date. Read SEC document |
| July 25, 2025 Filed Jul 29, 2025 23:02 UTC | ImageneBio, Inc. IMA · Entity 7139 | GrantCommon Stock | 3,051 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-020511 · form4-07292025_110730.xml · nonDerivative · entry 1 Butler Erin · CIK 0001940413 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,051 F1 · kind: Received in exchange for 1,000,000 ordinary shares of Inmagene Biopharmaceuticals ("Legacy Inmagene") pursuant to Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Merger Sub I, a wholly-owned subsidiary of the Issuer ("Merger Sub I"), Merger Sub II, a wholly-owned subsidiary of the Issuer ("Merger Sub II") and Legacy Inmagene (the "Merger Agreement"). F2 · kind: Under the terms of the Merger Agreement, on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "Merger"), with Legacy Inmagene surviving the Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). Upon the closing of the First Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. to ImageneBio, Inc. F1 · price: Received in exchange for 1,000,000 ordinary shares of Inmagene Biopharmaceuticals ("Legacy Inmagene") pursuant to Agreement and Plan of Merger, dated as of December 23, 2024, by and among, the Issuer, Merger Sub I, a wholly-owned subsidiary of the Issuer ("Merger Sub I"), Merger Sub II, a wholly-owned subsidiary of the Issuer ("Merger Sub II") and Legacy Inmagene (the "Merger Agreement"). F2 · price: Under the terms of the Merger Agreement, on July 25, 2025, Merger Sub I merged with and into Legacy Inmagene (the "Merger"), with Legacy Inmagene surviving the Merger as a wholly-owned subsidiary of the Issuer, and immediately after the First Merger, Legacy Inmagene merged with and into Merger Sub II, with Merger Sub II surviving the Merger as a wholly-owned subsidiary of the Issuer (the "Second Merger" and together with the First Merger, the "Merger"). Upon the closing of the First Merger, each Legacy Inmagene ordinary and preferred share was converted into the right to receive 0.003051 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Ikena Oncology, Inc. to ImageneBio, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.